Show Summary Details
Page of

Riluzole for Amyotrophic Lateral Sclerosis 

Riluzole for Amyotrophic Lateral Sclerosis
Riluzole for Amyotrophic Lateral Sclerosis

Brian Mac Grory

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 10 July 2020

This chapter provides a summary of a landmark study in neuromuscular disease. Is there a benefit in terms of survival and functional status to treating patients with amyotrophic lateral sclerosis with riluzole? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. Researchers reported that riluzole increased rates of survival and decreased the rate of muscle strength deterioration in patients with amyotrophic lateral sclerosis. This increased survival was most pronounced in those with bulbar-onset disease, and the trial failed to show a significant benefit for those with limb-onset disease. The chapter briefly reviews other relevant studies and information, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.